MCM
PHAS

MAI Capital Management’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

MAI Capital Management’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,307,534
Closed -$406K – 1072
2022
Q3 		$406K Buy
2,307,534
+598,430
+35% +$611K 0.01% 619
2022
Q2 		$1.02M Buy
1,709,104
+290,825
+21% +$278K 0.02% 367
2022
Q1 		$1.87M Buy
+1,418,279
New +$2.3M 0.03% 280

Other funds holding PHAS

DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HLA
Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return
IIA
IPG Investment Advisors San Diego, California $582M AUM 33.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

MAI Capital Management's PHAS Position: Q4 2022 in Review

MAI Capital Management sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2022, closing a stake of 2,307,534 shares — an estimated $406K sold.

MAI Capital Management first reported a position in PHAS in Q1 2022 and held it in 3 quarters. The position peaked at $1.87M in Q1 2022. 5 funds tracked by Wall St. Rank hold PHAS as of Q4 2022.

  • MAI Capital Management reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • MAI Capital Management sold 2,307,534 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $406K.
  • MAI Capital Management first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q1 2022 and held it in 3 quarters.
  • MAI Capital Management's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $1.87M in Q1 2022.
  • 5 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on MAI Capital Management's 13F filing for Q4 2022, filed 9 Feb 2023.